JAK2 and cancer: In fact, penfluridol was shown to target the JAK2 binding site in PRLR, thereby suppressing JAK2–STAT3 and ERK/AKT signaling, which are key players in cancer cell proliferation, migration, apoptosis and in conferring stem-cell features.